CClinicalTrials.gg
RecruitingNCT01166893Updated Dec 10, 2025

Ability of Modulated Imaging and Laser Speckle Imaging to Determine Burn Wound Severity and Healing Potential

An observational study in Skin Burn Multiple, sponsored by University of California, Irvine. Recruiting at 1 site in United States. Open to participants aged 1 Minute and older. Per ClinicalTrials.gov, last updated 2025-12-10.

Sponsored by University of California, Irvine · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
200
Ages
1 Minute and older
Sex
All
01

Study summary

According to the National Burn Repository 2007, the most common type of burn injury is a partial thickness burns. The current standard of care for partial thickness burns is two weeks of topical therapy and wound care. Burns that do not heal within two weeks undergo surgical excision and skin grafting.

Read the detailed description

Researcher can use the combination of Modulated Imaging and Laser Speckle Imaging can be used as an adjuvant to standard clinical evaluation to gauge burn wound and severity of infection. Researcher can image the burn wounds of and compare with current standard of care, clinical exam, and can use the outcomes information in terms of time to healing and treatment

Modulating Imaging is a noninvasive optical modality measure the metabolic functions of the burn wound.

Laser Speckle Imaging is a noninvasive optical modality can measure blood flow of burn wound.

02

Conditions studied

  • Skin Burn Multiple

Browse trials for

Keywords

  • burn wound
03

In context

Burns

719 studies on the registry are indexed under Burns; 145 are open to participants now.

This study's planned enrollment of 200 is above the median of 55 across 135 observational studies indexed under Burns.

Browse Burns studies →

Lead sponsor

University of California, Irvine is the lead sponsor of 466 studies on the registry; 96 are open to participants now.

Of its 41 completed or terminated interventional studies of FDA-regulated products, 30 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Minute and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Study population will be selected from University of California Irvine Medical Center Burn Unit.

Inclusion criteria

  1. Male / female all age
  2. Subjects is an inpatient or out patient with burn wound

Exclusion criteria

Exclusion Criteria:

  1. Subjects cannot lied flat and still for the duration of the imaging
  2. Subjects pregnant.
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
200 participants (estimated)

Groups and cohorts

  • Burn wound

    Modulated Imaging and Laser Speckle Imaging

    Device: Modulated Imaging and Laser Speckle Imaging

Interventions

  • DeviceModulated Imaging and Laser Speckle Imaging

    wound healing

    Also known as: MI-LSI developed at UCI Beckman Laser Institute

06

What researchers measure

Primary outcomes

  1. Noninvasive burn wound severity assessment

    Noninvasive burn wound severity assessment using noncontact optical device

    Time frame: 1 day

07

Study locations

1 of 1 sites recruiting
  • UCIMC
    Orange, California 92868, United States
    • Victor Joe, MD · Contact · 714-456-5840
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01166893
Lead sponsor
University of California, Irvine
Collaborators
National Institute of General Medical Sciences (NIGMS)
Responsible party
Anthony Joseph Durkin (Associate Professor, Director, Laboratory for Functional Imaging and Spectroscopy of Superficial Tissues, University of California, Irvine) — Principal investigator
First posted
Jul 21, 2010
Start date
Mar 2010
Primary completion
Feb 2028 (estimated)
Completion
Feb 2030 (estimated)
Last update
Dec 10, 2025

Study contacts

Gordon Kennedy, PhD
Contact
gordon.kennedy@uci.edu
949-824-4713
Anthony Durkin, PhD
principal investigator · University of California, Irvine

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion